Nephros Inc. (NASDAQ:NEPH - Get Free Report)'s stock price fell 14.2% during trading on Monday . The stock traded as low as $3.90 and last traded at $4.29. 143,052 shares were traded during mid-day trading, an increase of 768% from the average session volume of 16,484 shares. The stock had previously closed at $5.00.
Nephros Stock Performance
The stock has a market cap of $40.92 million, a PE ratio of 55.15 and a beta of 0.96. The company's 50 day simple moving average is $2.79 and its 200 day simple moving average is $2.02.
Nephros (NASDAQ:NEPH - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported $0.05 EPS for the quarter. Nephros had a return on equity of 9.43% and a net margin of 5.16%. The business had revenue of $4.88 million for the quarter, compared to analyst estimates of $3.67 million.
Institutional Trading of Nephros
A hedge fund recently bought a new stake in Nephros stock. Topline Capital Management LLC acquired a new stake in Nephros Inc. (NASDAQ:NEPH - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 419,887 shares of the company's stock, valued at approximately $617,000. Topline Capital Management LLC owned approximately 3.98% of Nephros as of its most recent filing with the SEC. 41.10% of the stock is currently owned by hedge funds and other institutional investors.
About Nephros
(
Get Free Report)
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Stories
Before you consider Nephros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nephros wasn't on the list.
While Nephros currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
